Welcome to our dedicated page for Stereotaxis Ord SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stereotaxis, Inc. filings document an operating medical-technology company focused on robotic systems and instruments for minimally invasive endovascular intervention. Recent Form 8-K reports record operating and financial results, product and regulatory information included in earnings materials, and material-event disclosures.
The company’s SEC record also includes a definitive proxy statement covering annual-meeting and shareholder voting matters, governance, executive compensation, and director elections. Capital-structure filings describe common stock, shelf registration use, and an at-the-market sales agreement for working capital, research and development, and commercialization of the company’s innovation pipeline.
Stereotaxis, Inc. furnished its third‑quarter 2025 financial results via a press release attached as Exhibit 99.1 to an 8‑K. The company noted that statements in the release may include forward‑looking statements subject to risks and uncertainties. Under General Instruction B.2, the information in Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and will be incorporated by reference only if expressly cited in future filings.
Stereotaxis, Inc. may offer and sell up to $50 million of its common stock through an at-the-market program under a Sales Agreement with Roth Capital Partners. Shares can be sold from time to time on the NYSE American or in other permitted transactions, with Roth acting as sales agent or, on occasion, as principal.
Roth will receive up to 3.0% of the gross proceeds from any shares sold, plus expense reimbursements, and will be deemed an underwriter for regulatory purposes. Assuming an illustrative sale of 17,421,602 shares at $2.87 per share, total common stock outstanding would rise to 108,493,081 shares, which would dilute existing holders.
Stereotaxis intends to use any net proceeds for working capital, research and development, and other general corporate purposes, including accelerating commercialization of its innovation pipeline. The company notes that its common stock does not currently pay cash dividends, so potential returns would primarily depend on share price appreciation.
Stereotaxis, Inc. entered into a Sales Agreement with Roth Capital Partners that allows the company to sell shares of its common stock with an aggregate sales price of up to $50,000,000 through at-the-market offerings or privately negotiated transactions. These potential sales are covered by an existing Form S-3 shelf registration that permits up to $100,000,000 of securities, with a new prospectus supplement dated August 29, 2025.
Roth Capital will act as sales agent and/or principal and earn a placement fee of up to 3.0% of the gross sales price of any shares sold, plus specified expense reimbursements. Stereotaxis plans to use any net proceeds for working capital, research and development, and other general corporate purposes, including accelerated commercialization of its innovation pipeline. The company is not obligated to sell any shares, and the program can be suspended or terminated by either party under the agreement’s terms.
Stereotaxis, Inc. reported stronger top-line results for the quarter ended June 30, 2025, with total revenue of $8.8 million, up from $4.5 million a year earlier, and $16.3 million for the six months versus $11.4 million in 2024. Growth was driven by higher systems sales ($3.0 million in Q2 2025 versus $0.24 million) and increased disposables, service and accessories revenue. Gross margin improved to $4.6 million in the quarter from $3.3 million a year ago, and operating loss narrowed to $4.0 million from $6.0 million in the prior-year quarter.
Despite improved operating performance, the company remains unprofitable with a six-month net loss of $9.6 million and a cumulative deficit of approximately $571.4 million. Cash and cash equivalents were $6.97 million at June 30, 2025, and operating cash used was $5.5 million for the six months. The company completed an earlier acquisition of Access Point Technologies (APT), recognized related intangible assets and goodwill, recorded a $0.5 million contingent consideration revaluation charge, and disclosed a July 2025 registered offering with initial gross proceeds of $8.5 million and $4.0 million expected at a later closing.